News

Investing in early-stage cell therapy developers article published in Cell and Gene Insights

Stockholm 21st of February 2025 - Alder co-founders Stijn Heessen (COO) and Kristian Tryggvason (CEO) shared their viewpoint on investing in cell therapy companies in this recent article in Cell & Gene Therapy Insights.

Providing a future, healthy and competitive commercial cell therapy landscape depends on young companies having early access to sufficient capital to advance new transformational and complementary cell therapies. It will thus fall on the starting companies to further educate the investment community on the particular attributes of cell therapy development and how it differs from developing other, well-established therapeutic modalities.

External link to article:
https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3434/investing-in-earlystage-stem-cell-therapy-developers

About Alder Therapeutics

Alder Therapeutics is a virtual pre-clinical replacement cell therapy development company that is shaping the future of regenerative medicine. Founded in 2022 by seasoned cell therapy and industry experts, the company has two promising allogeneic stem cell therapy programs in the pipeline: one for degenerative eye diseases, and one for chronic heart disease. At the core of the company’s success is the AlderEdge™ platform — a novel approach to cell therapy development that keeps the commercial product in mind from the start for a de-risked route to success.

For more information:

Kristian Tryggvason
CEO
Alder Therapeutics
kristian@aldertx.com